JP2021530511A5 - - Google Patents

Info

Publication number
JP2021530511A5
JP2021530511A5 JP2021501327A JP2021501327A JP2021530511A5 JP 2021530511 A5 JP2021530511 A5 JP 2021530511A5 JP 2021501327 A JP2021501327 A JP 2021501327A JP 2021501327 A JP2021501327 A JP 2021501327A JP 2021530511 A5 JP2021530511 A5 JP 2021530511A5
Authority
JP
Japan
Prior art keywords
seq
cancer
composition according
disease
lcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021501327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530511A (ja
JP7519985B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/096679 external-priority patent/WO2020015722A1/en
Publication of JP2021530511A publication Critical patent/JP2021530511A/ja
Publication of JP2021530511A5 publication Critical patent/JP2021530511A5/ja
Application granted granted Critical
Publication of JP7519985B2 publication Critical patent/JP7519985B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021501327A 2018-07-19 2019-07-19 抗pd-1抗体、投薬量、およびその使用 Active JP7519985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/096206 2018-07-19
CN2018096206 2018-07-19
PCT/CN2019/096679 WO2020015722A1 (en) 2018-07-19 2019-07-19 Anti-pd-1 antibodies, dosages and uses thereof

Publications (3)

Publication Number Publication Date
JP2021530511A JP2021530511A (ja) 2021-11-11
JP2021530511A5 true JP2021530511A5 (cg-RX-API-DMAC7.html) 2022-07-22
JP7519985B2 JP7519985B2 (ja) 2024-07-22

Family

ID=69164151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021501327A Active JP7519985B2 (ja) 2018-07-19 2019-07-19 抗pd-1抗体、投薬量、およびその使用

Country Status (5)

Country Link
US (1) US12258407B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823991A4 (cg-RX-API-DMAC7.html)
JP (1) JP7519985B2 (cg-RX-API-DMAC7.html)
CN (1) CN112424231B (cg-RX-API-DMAC7.html)
WO (1) WO2020015722A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7275030B2 (ja) 2017-01-20 2023-05-17 タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド 抗pd-1抗体およびその使用
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP2021525806A (ja) 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド 疾患または状態を処置するための組成物およびそれらの使用
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
CA3181776A1 (en) 2020-05-26 2021-12-02 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
PE20241732A1 (es) 2021-03-31 2024-08-19 Merus Nv Dominios de union a pd-1 novedosos

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6190370B1 (en) 1997-07-25 2001-02-20 Arrow International, Inc. Devices, systems and methods for determining proper placement of epidural catheters
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) * 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
KR102524920B1 (ko) 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
CA2968680A1 (en) 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
CN104479020B (zh) 2014-12-26 2019-08-02 上海复宏汉霖生物技术股份有限公司 一种抗pd-1人源抗体
CN105061597B (zh) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
RU2722451C1 (ru) * 2015-09-29 2020-06-01 Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. Pd-1 антитела и их применение.
PL3368572T5 (pl) 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
CN105175544B (zh) 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用
CN105566496B (zh) 2015-11-26 2019-04-02 大庆东竺明生物技术有限公司 阻断人程序性死亡因子1(pd-1)功能的单克隆抗体及其编码基因和应用
CN106008714B (zh) 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
US10669338B2 (en) * 2016-06-17 2020-06-02 Immunomedics, Inc. Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
MX2019002946A (es) * 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
CN108203464B (zh) * 2016-12-25 2021-07-20 南京金斯瑞生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-1抗体
JP7275030B2 (ja) 2017-01-20 2023-05-17 タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド 抗pd-1抗体およびその使用

Similar Documents

Publication Publication Date Title
JP2020505386A5 (cg-RX-API-DMAC7.html)
US11981733B2 (en) LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
JP2021521843A5 (cg-RX-API-DMAC7.html)
US10442857B2 (en) Anti-IL-17 antibodies
JP2015510510A5 (cg-RX-API-DMAC7.html)
JP2018537400A5 (cg-RX-API-DMAC7.html)
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
RU2014136332A (ru) Композиции и способы применения ингибиторов csf1r
RU2018111508A (ru) Анти-LAG-3 антитела
JP2012500020A5 (cg-RX-API-DMAC7.html)
JP2016538876A5 (cg-RX-API-DMAC7.html)
JP2020511946A5 (cg-RX-API-DMAC7.html)
HRP20200583T1 (hr) Protutijela koja neutraliziraju gp120 i njihova upotreba
JP2019522961A5 (cg-RX-API-DMAC7.html)
JP2018521691A5 (cg-RX-API-DMAC7.html)
JP2012526558A5 (cg-RX-API-DMAC7.html)
KR20040095291A (ko) 인간화 항체 및 이의 제조방법
JP2022529154A5 (cg-RX-API-DMAC7.html)
JP2024516595A5 (cg-RX-API-DMAC7.html)
JP6466904B2 (ja) インターフェロンアルファ及びオメガ抗体アンタゴニスト
CN112513087B (zh) 抗cd38抗体、其抗原结合片段及医药用途
JP2023531493A5 (cg-RX-API-DMAC7.html)
HRP20241488T1 (hr) Protutijela anti-pd-1
WO2019230869A1 (ja) 抗ヒトtlr7抗体
JPWO2022044573A5 (cg-RX-API-DMAC7.html)